Jeff Johnson

Statistics

Publications

Citations

H-Index

Active since

2023

Affiliations

CymaBay Therapeutics (United States)(Current)

Jeff Johnson is an author at CymaBay Therapeutics (United States) specializing in peroxisome proliferator-activated receptor signaling, liver disease, and pruritus management.

Publications per year

2023–2023

Publications

Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis

Andreas E. Kremer, Marlyn J. Mayo, Gideon M. Hirschfield et al. · Hepatology · 2023 · 48 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +16

Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis

Yun‐Jung Choi, Jeff Johnson, Jin-Ju Lee et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2023 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–2 of 2